EXPANDED ACCESS DATA IMPACT ON NDAs SHOULD BE ASSESSED BY FDA, REFORM BILL CONFERENCE REPORT STATES; "FAST TRACK" PROVISIONS CODIFY ACCELERATED APPROVAL
Executive Summary
FDA should study the impact of compassionate use and expanded access data on NDA submissions in order to make sponsors more comfortable with the programs, the House/Senate FDA reform bill conference report directs.
You may also be interested in...
Hemispherx Ampligen NDA Plans Could Pose Challenge For FDA
An upcoming NDA filing for Hemispherx' chronic fatigue syndrome agent Ampligen may offer a sensitive case for FDA as it implements Commissioner McClellan's "strategic plan" for the agency
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011